At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years
- ✓Primary, recurrent, localized, or metastatic head and neck cancer (AJCC 8th Edition stages I-IV)
- ✓Pathologic confirmation required for primary diagnosis; may be waived for recurrent/metastatic cases if not standard of care
- ✓Ineligible for or declines standard of care definitive treatment
- ✕Pregnant or breast-feeding
- ✕More than 1 prior radiation treatment course to treatment area, or ≥1 prior course if <6 months since completion
- ✕Comorbidity or condition limiting full protocol compliance
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)
In Brief
A clinical study evaluating Personalized ultrafractionated stereotactic adaptive radiotherapy, Volume Modulated Arc Therapy, and 6 other interventions for Head and Neck Carcinoma and 3 related conditions. Currently recruiting, targeting 43 participants across 1 site.
Detailed Summary
This trial tests how well personalized ultra fractionated stereotactic adaptive radiotherapy (PULSAR) works together with HyperArc© radiation treatment planning technology for palliative (holistic pain and symptom control) tumor control in patients with primary or recurrent, localized or metastatic head and neck cancer (HNC) who are ineligible for or decline standard of care treatment. Researchers want to evaluate if using HyperArc and PULSAR together will deliver higher, possibly more effective doses, resulting in better tumor control with the same or fewer side effects than smaller routine doses. PULSAR is a radiation therapy regimen that uses a limited number of fairly large dose pulses while adjusting to specific anatomic and/or biological changes which may occur during the course of the treatment. HyperArc radiation treatment planning technology is a tool that allows for target dose escalation to tumor tissue while maintaining minimal head and neck organs-at-risk doses compared to other radiation treatment planning software. Undergoing PULSAR and HyperArc technology together may be a safe and effective palliative treatment option for patients with HNC.
Study Details
Timeline
Interventions
PULSAR is a radiation therapy regimen that uses a limited number of fairly large dose pulses while adjusting to specific anatomic and/or biological changes which may occur during the course of the treatment.
Use HyperArc technology
Undergo CT simulation for radiation planning
Undergo PET
Undergo MRI
Undergo standard of care
Complete questionnaire
Complete questionnaire